Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Card: All Sponsors Return For 2005 Run-Up To Part D Benefit

This article was originally published in The Pink Sheet Daily

Executive Summary

Re-enrollment period for 2005 Medicare drug discount card program offers all 34 national cards currently available. Sponsors' continued interest speaks to the program's importance as a "loss leader" to participating in the Part D drug benefit market in 2006.
Advertisement

Related Content

Medicare Rx Plan Numbers Will Not Match Card Sponsor Totals, CMS’ McClellan Predicts
Medicare Rx Plan Numbers Will Not Match Card Sponsor Totals, CMS’ McClellan Predicts
Discount Card Enrollment Runs “Way Ahead” Of Similar Programs – McClellan
Discount Card Enrollment Runs “Way Ahead” Of Similar Programs – McClellan
Express Scripts Is Optimistic About Medicare Rx Card Auto-Enrollment
Caremark May Offer Medicare Rx Plan If Risk Is Minimized, CEO Says
Caremark May Offer Medicare Rx Plan If Risk Is Minimized, CEO Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS058428

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel